Last updated on July 2019

FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation


Brief description of study

Single-arm, multi-centre phase II study The primary objective is to evaluate the time to failure of the strategy.

Detailed Study Description

The purpose of the OPTIPRIME phase II non-randomised study is to evaluate the efficacy and tolerability of the combination of FOLFOX plus panitumumab according to a "stop and go" strategy. If disease control is achieved while on induction treatment, oxaliplatin and panitumumab will be stopped after the sixth cycle; a maintenance treatment of fluoropyrimidine alone will be continued. In case of progression during maintenance treatment, oxaliplatin and panitumumab reintroduction loops will take place according to the same regimen (maintenance treatment after six cycles of the reintroduced therapy if disease control is achieved).

Clinical Study Identifier: NCT03584711

Find a site near you

Start Over

Clinique Trenel

Sainte Colombe, France
  Connect »

Chu D'Angers

Angers CEDEX 9, France
  Connect »

Service de Medecine

Digne-les-Bains, France
  Connect »

Centre Hospitalier General

Châlons-en-Champagne, France
  Connect »

Polyclinique Saint Privat

Boujan-sur-Libron, France
  Connect »

Ch Du Mans

Le Mans CEDEX 9, France
  Connect »

CH

Dunkerque CEDEX 01, France
  Connect »

Ch Cote Basque

Bayonne CEDEX, France
  Connect »

Cmco Cote D'Opale

Boulogne-sur-Mer, France
  Connect »

Hopital Duchenne

Boulogne-sur-Mer, France
  Connect »

Ch Cahors

Cahors, France
  Connect »

Centre Hospitalier General

Châlons-en-Champagne, France
  Connect »

Chd Vendee

La Roche-sur-Yon, France
  Connect »

Hopital Layne

Mont-de-Marsan, France
  Connect »

Centre Hospitalier

Saint-Quentin CEDEX, France
  Connect »

Chu de Fort de France

Fort-de-France, Martinique
  Connect »

Centre Hospitalier General

Châlons-en-Champagne, France
  Connect »